News

Amphix Bio lands federal and state grants to manufacture regenerative therapies
October 31, 2024
​
Amphix Bio announced that it has secured a $1M Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation to scale up manufacturing methods for its platform technology of supramolecular peptide therapeutics.
​
​
​​

FDA grants Breakthrough Device designation to Amphix Bio’s bone regeneration product
October 3, 2024
​
Amphix Bio, a company developing a new class of regenerative medicine therapies, announced today it has received a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for a drug-device combination product for bone regeneration.
​
​​

Stupp Lab uses supramolecular therapeutics platform to grow cartilage
July 26, 2024
​
Professor Samuel Stupp's group at Northwestern University published work demonstrating that supramolecular motion is a key factor in biological signaling for cartilage regeneration. Stupp is the co-founder and Chief Scientific Officer of Amphix Bio.​​

Amphix Bio bolsters operations with new hires​
May 1, 2024
​
Amphix Bio has announced the additions of Hussain Sangji as Director of Operations and Iwona Maciagiewicz as CMC Director. They join the company as it is scaling up production, initiating regulatory filings with the FDA, and gearing up for first-in-human clinical trials.
​​
​​​

Regenerative nanomaterial enables spinal fusion with minimal growth factor
October 17, 2023
​
Scientists at Northwestern University published a new study describing a novel therapeutic for bone regeneration that induced spinal fusion with a 100-fold dose reduction in recombinant BMP-2 compared to current clinical products.​
​

Amphix Bio secures SBIR award to advance regenerative technology for spinal fusion
February 24, 2022
​
Amphix Bio has received a Small Business Innovation Research (SBIR) Phase I grant from the National Science Foundation to advance a new bone regeneration technology for treating debilitating back pain caused by degenerative disc disease.​​
​
​

Groundbreaking injectable therapy repairs severe spinal cord injuries
November 11, 2021
​
Researchers led by Samuel Stupp have developed a new injectable therapy that harnesses supramolecular motion to reverse paralysis and repair tissue after severe spinal cord injuries. ​​
​
​
Videos
Amphix Bio co-founder Samuel Stupp was featured in more than 350 news stories after his laboratory published research on an injectable therapeutic for spinal cord injury. Watch the video packages below from Northwestern University and BBC News to learn more about this research.